Companies › Alvotech Swiss
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology, Ophthalmology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AVT29 VEGF-A inhibitor (proposed aflibercept HD biosimilar) | VEGFA | Phase 3 | Diabetic Macular Edema | Jul 2027 |
| AVT32-DRL_PB PD-1 inhibitor (pembrolizumab biosimilar) | PDCD1 | Phase 1 | Melanoma | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07489131 | AVT29 | Phase 3 | Diabetic Macular Edema | Ophthalmology | Jul 2027 |
| NCT07475572 | AVT32-DRL_PB | Phase 1 | Melanoma | Oncology | Oct 2027 |
Samsung Bioepis Binhui Biopharmaceutical Shanghai Juncell Therapeutics CrystalGenomics Intra-IMMUSG Pte
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.